Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference
Alkermes plc (Nasdaq: ALKS) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 10:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 10:30 a.m. ET. The event will be available under the Investors tab on their website and archived for 14 days. Alkermes is a global biopharmaceutical company focused on developing innovative medicines for neuroscience and oncology, with a portfolio addressing addiction, schizophrenia, and bipolar I disorder.
Positive
- Participation in a high-profile global healthcare conference, which may increase visibility and investor interest.
- The company has a diverse product portfolio focused on critical mental health issues, indicating potential for strong market demand.
Negative
- None.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was +0.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET (3:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-goldman-sachs-annual-global-healthcare-conference-301305712.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.